Haematological cancer articles within Nature Communications

Featured

  • Article
    | Open Access

    ELL2 was recently discovered as a susceptibility gene for multiple myeloma (MM). Here, they show that the MM risk allele lowers ELL2 expression in plasma cells, that it also upregulates gene sets related to ribosome biogenesis, and that one of the linked variants reduces binding of MAFF/G/K family transcription factors.

    • Mina Ali
    • , Ram Ajore
    •  & Björn Nilsson

  • Article
    | Open Access

    Gene fusions involving MLL and different partner genes define unique subgroups of acute myelogenous leukemia, but the mechanisms underlying specific subgroups are not fully clear. Here the authors elucidate the mechanisms of MLL-AF6 induced transformation, providing a distinct pathway that involves SHARP1 as a critical target.

    • Akihiko Numata
    • , Hui Si Kwok
    •  & Daniel G. Tenen

  • Article
    | Open Access

    Aggressive natural killer-cell leukemia (ANKL) has few targeted therapies. Here ANKL patients are reported to harbor STAT3, RAS-MAPK pathway, DDX3X and epigenetic modifier mutations; and drug sensitivity profiling uncovers the importance of the JAK-STAT pathway, revealing potential ANKL therapeutic targets.

    • Olli Dufva
    • , Matti Kankainen
    •  & Satu Mustjoki

  • Article
    | Open Access

    Metabolic rewiring of cancer cells can be driven by both extrinsic and intrinsic factors. Here the authors show that microenvironmental factors induce metabolic rewiring of B-cell lymphoma through activation of STAT3 and NF-ΚB resulting in upregulation of the aminotransferase GOT2 and glutamine addiction.

    • Maren Feist
    • , Philipp Schwarzfischer
    •  & Dieter Kube

  • Article
    | Open Access

    Myelofibrosis is a chronic degenerative disorder characterized by progressive bone marrow fibrosis. Here, the authors show that the chaperone HSP27 contributes to myelofibrosis via regulation of the JAK2/STAT5 pathway, and that antisense oligonucleotides targeting HSP27 are effective in two mouse models of the disease

    • Margaux Sevin
    • , Lucia Kubovcakova
    •  & Aurélie de Thonel

  • Article
    | Open Access

    Promyelocytic leukemia protein (PML) is a scaffolding protein that organizes PML nuclear bodies. Here the authors present the tetrameric crystal structure of the PML RING domain and show that RING tetramerization is functionally important for nuclear body formation and PML sumoylation.

    • Pengran Wang
    • , Shirine Benhenda
    •  & Guoyu Meng

  • Article
    | Open Access

    Activation-induced deaminase (AID) is important for inducing desirable mutations at the B cell receptor genes for effective antibody responses. Here the authors show that three key arginine residues of AID link AID-chromatin association with transcription elongation to license AID for specific mutagenesis in B cells.

    • Stephen P. Methot
    • , Ludivine C. Litzler
    •  & Javier M. Di Noia

  • Article
    | Open Access

    IKZF1 is a transcription factor known to regulate mammalian B-cell development. Here the authors show that IKZF1 is required for human pDC development and regulation of DC cytokine production in patients with IKZF1 haploinsufficiency, findings which are recapitulated in lenalidomide-induced IKZF1 deficiency.

    • Urszula Cytlak
    • , Anastasia Resteu
    •  & Venetia Bigley

  • Article
    | Open Access

    Resistance to chemotherapy is a serious issue that can be influenced by RNA epigenetics and chromatin structure. Here, the authors show in leukaemia cells that RNA 5-methylcytosine (RNA:m5C) and RNA:m5C methyltransferases (RCMTs) mediate chromatin structures that can modulate 5-Azacitidine response and resistance.

    • Jason X. Cheng
    • , Li Chen
    •  & James W. Vardiman

  • Article
    | Open Access

    Aberrant protein translation and uncontrolled lipid metabolism are hallmarks of cancer growth. Here, in diffuse large B-cell lymphoma, the authors show that fatty acid synthase increases USP11 interaction with and stability of eIF4B via PI3K-S6Kinase signaling, promoting oncogenic protein translation.

    • Bandish Kapadia
    • , Nahid M. Nanaji
    •  & Ronald B. Gartenhaus

  • Article
    | Open Access

    T-cell prolymphocytic leukemia (T-PLL) is a rare malignancy with a poor prognosis. Here, the authors investigate the genomic landscape, gene expression profiles and functional mechanisms in 111 patients, highlighting TCL1 overexpression and ATM aberrations as core lesions which co-operate to impair DNA damage processing.

    • A. Schrader
    • , G. Crispatzu
    •  & M. Herling

  • Article
    | Open Access

    MYB activity is a key factor for the maintenance of acute myeloid leukemias but it is also a difficult target. Here, the authors develop a peptidomimetic (MYBMIM) that prevents the interaction of the trans-activation domain of MYB with the KIX domain of CBP/P300 and inhibits leukaemia growth.

    • Kavitha Ramaswamy
    • , Lauren Forbes
    •  & Alex Kentsis

  • Article
    | Open Access

    Persistence of resistant leukemic cells after therapy is the main cause of relapse. Here, the authors show that mesenchymal stem cells-derived PML is involved in the maintenance of leukemia cells through Cxcl1 and IL6 and that PML inhibition enhances sensitivity to chemotherapy.

    • Jlenia Guarnerio
    • , Lourdes Maria Mendez
    •  & Pier Paolo Pandolfi

  • Article
    | Open Access

    The treatment of multiple myeloma is challenging due to high relapse rates. Here the authors show that expression of ADAR1 correlates with poor patient outcomes, and that ADAR1-mediated editing of GLI1 is a mechanism relevant in the context of multiple myeloma progression and drug resistance.

    • Elisa Lazzari
    • , Phoebe K. Mondala
    •  & Catriona H. M. Jamieson

  • Article
    | Open Access

    Dendrogenin A, cholesterol metabolite, has tumor suppressive properties but the mechanisms are unknown. Here the authors show that Dendrogenin A can induce autophagy-mediated cell death in both melanoma and acute myeloid leukaemia.

    • Gregory Segala
    • , Marion David
    •  & Sandrine Silvente-Poirot

  • Article
    | Open Access

    Classical Hodgkin lymphoma is a cancer that originates in lymph nodes. Little is known about its genetic susceptibility. Here, the authors combined existing and new genome-wide association studies to identify risk loci for classical Hodgkin lymphoma at 6q22.33, and nodular sclerosis Hodgkin lymphoma at 3q28, 6q23.3, 10p14, 13q34, 16p13.13.

    • Amit Sud
    • , Hauke Thomsen
    •  & Richard S. Houlston

  • Article
    | Open Access

    Multiple myeloma is a malignancy of plasma cells in the blood. Here, the authors establish the landscape of fusion genes within this disease, identifying novel recurrent fusion genes that impact survival and may drive disease progression.

    • A. Cleynen
    • , R. Szalat
    •  & H. Avet-Loiseau

  • Article
    | Open Access

    Checkpoint kinase 1 (CHK1) is critical for intrinsic cell cycle control and coordination of cell cycle progression. Here the authors show that CHK1 loss or chemical inhibition impacts on normal B cell development, lymphomagenesis and cancer cell survival.

    • Fabian Schuler
    • , Johannes G. Weiss
    •  & Andreas Villunger

  • Article
    | Open Access

    Myelodysplastic syndromes (MDS) are uncommon in children and have poor prognosis. Here, the authors interrogate the genomic landscape of MDS, confirming adult and paediatric MDS are separate diseases with disparate mechanisms, and highlighting that SAMD9/SAMD9L mutations represent a new class of MDS predisposition.

    • Jason R. Schwartz
    • , Jing Ma
    •  & Jeffery M. Klco

  • Article
    | Open Access

    Several rearrangements of the MLL gene are associated with acute leukemia, including the fusion of MLL with a RAS effector protein, AF6. Here the authors show that the truncated AF6 can induce AF6-MLL dimerization and drive its oncogenic activity.

    • Matthew J. Smith
    • , Elizabeth Ottoni
    •  & Mitsuhiko Ikura

  • Article
    | Open Access

    NFAT2 is a transcription factor that has been linked with chronic lymphocytic leukaemia (CLL), but its functions in CLL manifestation are still unclear. Here the authors show, by analysing mouse CLL models and characterising biopsies from CLL patients, that NFAT2 is an important regulator for the anergic phenotype of CLL.

    • Melanie Märklin
    • , Jonas S. Heitmann
    •  & Martin R. Müller

  • Article
    | Open Access

    FAM46C is one of the most frequently mutated genes in multiple myeloma (MM), but its molecular function remains unknown. Here the authors show that FAM46C is a poly(A) polymerase and that loss of function of FAM46C drives multiple myeloma through the destabilisation of ER response transcripts.

    • Seweryn Mroczek
    • , Justyna Chlebowska
    •  & Andrzej Dziembowski

  • Article
    | Open Access

    While micro-RNAs are known regulators of haematopoiesis and leukemogenesis, the role of long non-coding RNAs is less clear. Here the authors provide a non-coding RNA expression landscape of the human hematopoietic system, highlighting their role in the formation and maintenance of the human blood hierarchy.

    • Adrian Schwarzer
    • , Stephan Emmrich
    •  & Jan-Henning Klusmann

  • Article
    | Open Access

    C/EBPα is a critical transcription factor involved in myelopoiesis and its inactivation is associated with acute myeloid leukemia (AML). Here the authors show a negative feedback loop between C/EBPα and miR-182 and identify this miRNA as a marker of high-risk AML.

    • Alexander Arthur Wurm
    • , Polina Zjablovskaja
    •  & Gerhard Behre

  • Article
    | Open Access

    ASXL2 mutations are mostly found in a subset of leukemia patients with certain genetic aberrations; however the role of this protein in normal hematopoiesis and related malignancies is still unclear. Here the authors use a knock-out mouse model to uncover the role of Asxl2in hematopoiesis and leukemogenesis.

    • Jianping Li
    • , Fuhong He
    •  & Feng-Chun Yang

  • Article
    | Open Access

    Human T-cell leukaemia virus type-1 and bovine leukaemia virus infect T and B lymphocytes and lead to aggressive leukaemia. Here, the authors show these proviruses integrate near cancer drivers perturbing transcription termination or antisense RNA-dependent interaction, suggesting post-transcriptional mechanisms in some cases.

    • Nicolas Rosewick
    • , Keith Durkin
    •  & Anne Van den Broeke

  • Article
    | Open Access

    While the role of ASLX1 in haematopoiesis and leukaemia has been heavily studied, the role of ASLX2 is unclear. Here the authors show that ASLX2 is required for normal haematopoietic stem cell self-renewal whereas Asxl2 loss promotes leukemogenesis, thus explaining the frequently observed mutations in AML patients

    • Jean-Baptiste Micol
    • , Alessandro Pastore
    •  & Omar Abdel-Wahab

  • Article
    | Open Access

    Leukaemia cells resident in the bone marrow niche are often resistant to conventional therapies. In this study, the authors develop light-sensitive, polymeric, retinoic acid-containing nanoparticles that are able to modulate the differentiation of resistant leukaemia cells bothin vitro and in vivo.

    • Carlos Boto
    • , Emanuel Quartin
    •  & Lino Ferreira

  • Article
    | Open Access

    TET2 catalyses DNA demethylation and is mutated in various blood cancers; in particularTet2null mice develop haematological neoplasms. Here the authors show that this effect could be due to the increased frequency of mutation associated with TET2 loss in haematopoietic stem/progenitor cells.

    • Feng Pan
    • , Thomas S. Wingo
    •  & Mingjiang Xu

  • Article
    | Open Access

    Myelodysplastic syndromes are a broad group of haematopoietic malignancies that often progress to acute myeloid leukaemia. Here, the authors show that linear and branched evolution occurs within myelodysplastic syndrome and these patterns can be impacted by treatment.

    • Pedro da Silva-Coelho
    • , Leonie I. Kroeze
    •  & Joop H. Jansen

  • Article
    | Open Access

    Ibrutinib has demonstrated high response rates in B-cell lymphomas but a lot of ibrutinib-treated patients relapse with resistance. This study unified TME-mediatedde novoand acquired drug resistance through B-cell receptor signalling and PI3K-AKT-mTOR axis and provides a combination therapeutic strategy against B-cell malignancies.

    • Xiaohong Zhao
    • , Tint Lwin
    •  & Jianguo Tao

Browse broader subjects

Browse narrower subjects

Browse Haematological cancer across other nature.com journals